Method for predicting drug tolerance of endocrine medicament in estrogen receptor antagonists

Abstract

The invention discloses a method for predicting the drug tolerance of an endocrine medicament in estrogen receptor antagonists, which adopts a real-time quantitative method to detect the relative express level of ER alpha and ER beta in breast cancer so as to predict the drug tolerance of the endocrine medicament in the estrogen receptor antagonists. The method comprises the following steps: comparing the relative express level of ER alpha and ER beta genes of a target to be detected with that of a normal contrast, and analyzing the drug tolerance of the endocrine medicament in the estrogen receptor antagonists, wherein the drug tolerance of the endocrine medicament in the estrogen receptor antagonists is negative when the ratio of ER alpha / ER beta of the target to be detected is more than that of the normal contrast; and the drug tolerance of the endocrine medicament in the estrogen receptor antagonists is positive when the ratio of ER alpha / ER beta of the target to be detected is less than that of the normal contrast. The method for predicting the drug tolerance provides a feasible basis for directing the medication of the breast caner individuals in clinic, and can reduce thedrug tolerance reaction and side effect caused by blind use of drugs.

Description

technical field [0001] The invention belongs to the field of physiological and biochemical detection, and relates to a method for predicting drug resistance of estrogen receptor antagonist endocrine drugs based on detecting the relative expression levels of ERα and ERβ in breast cancer. Background technique [0002] Breast cancer is a hormone-induced tumor. About 1.2 million women around the world develop breast cancer every year, and 500,000 women die from breast cancer. In developed countries such as Western Europe and North America, the incidence of breast cancer ranks first among female malignant tumors; The incidence of breast cancer in my country has been rising continuously in recent years, and there is a trend of rejuvenation. According to the hormone-induced characteristics of breast cancer, patients have been treated with endocrine therapy for more than 100 years. Currently, estrogen receptor (ER) is used as a therapeutic target, and estrogen receptor antagonists a...

AI Technical Summary

Problems solved by technology

At present, when clinical laboratories use immunohistochemical methods to detect ER expression levels in breast cancer, most of the antibodies used only target ERα or cannot effectively distinguish ERα and ERβ

Clinical breast cancer tissue biopsy only considers whether to use tamoxifen-like estrogen receptor antagonists based on the expression of ERα, while ignoring the detection of ERβ, resulting in drug resistance and side effects such as endometrial cancer in some patients

Images